Faculty profile

Johann Hitzler

ResearcherDevelopmental and Stem Cell BiologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Johann Hitzler

Researcher

Developmental and Stem Cell Biology

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
24 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2015.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

267

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Acute Myeloid Leukemia Ancillary Study To Clinical Trial In Ds-Aml Digital Pcr Down Syndrome Error-Corrected Sequencing Gata1 Minimal Residual Disease Xenografts

Latest papers

IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.
Blood · 2026
DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia.
Blood advances · 2026
T-Cell Lymphoblastic Lymphoma in a Child With Trisomy 21: A Unique Case Demonstrates the Need for Malleability in Therapy.
Pediatric blood & cancer · 2026

All 62 publications

Latest funding

Preventing infection-related mortality in children with Down syndrome during treatment for acute lymphoblastic leukemia
CIHR · 2026 · Co-investigator
$921,824
Genetic modifiers of chemotherapy-induced neurotoxicity identified in recombinant inbred mice
CIHR · 2024 · Co-investigator
$1,105,426
How does chemotherapy to treat childhood cancer affect brain development?
CIHR · 2019 · Co-investigator
$933,300

All 6 grants and awards

62 publications.

IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.

Li X, Aguilar-Navarro AG, Nader M, Jahangiri S, Lee HS, Edun G, Gower M, Yang D, Fernandez M, Lin B, Oh D, Farhat S, Phillips DM, Bartman S, Murray D, Kaszuba C, Kossinna P, Kamath M, Whyne C, Schwartz G, Bajaj J, Kislinger T, Zhou BO, Coutu D, Akens M, Changoor A, Mallevaey T, Gaiti F, Jones C, Naik S, Minden M, Arruda A, Hitzler J, Lee KJ, Kim YM, Adams RH, Sivara KK, Tikhonova AN

Blood2026

DOI: 10.1182/blood.2025030946 PMID: 42008378

DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia.

Verboon LJ, Barwe SP, Tavenner M, Faust JR, Issa H, Gonçalves-Dias J, Schuschel K, Bhayadia R, van Berkel PH, Sebastian A, Ries RE, Paczesny S, Meshinchi S, Hitzler J, Pikman Y, Kolb EA, Heckl D, Klusmann JH, Gopalakrishnapillai A

Blood advances2026

DOI: 10.1182/bloodadvances.2025018830 PMID: 41945753

T-Cell Lymphoblastic Lymphoma in a Child With Trisomy 21: A Unique Case Demonstrates the Need for Malleability in Therapy.

Tape S, Winter S, Miller L, Hilgers M, Hitzler J, Rabin KR, Gossai N

Pediatric blood & cancer2026

DOI: 10.1002/1545-5017.70256 PMID: 41846322

Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.

Berman JN, Verma A, Viola S, Alonzo TA, Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, Ma X, Ries R, Meshinchi S, Gamis A, Schore R, Taub JW, Kolb EA, Cooper T, Hitzler J

Blood advances2026Senior author

DOI: 10.1182/bloodadvances.2025017837 PMID: 41124669

The "route cause" of methotrexate-induced brain structure changes in a juvenile mouse model: Comparison of systemic and CNS-targeted chemotherapy.

Choi SE, Ayoub T, Lee G, Wheeler AL, Guger SL, Weksberg R, Ito S, Schachar RJ, Hitzler J, Nieman BJ

Neurotoxicology2026

DOI: 10.1016/j.neuro.2025.103363 PMID: 41386426

Vincristine-induced brain toxicity is reduced with prevention of peripheral axon degeneration in Sarm1 knockout mice.

Yeung J, Hsu P, Mak J, Darbandi A, Wheeler AL, Weksberg R, Guger SL, Schachar RJ, Ito S, Hitzler J, Nieman BJ

Acta neuropathologica communications2025

DOI: 10.1186/s40478-025-02171-0 PMID: 41419972

Clinical utility of targeted RNA sequencing in cancer molecular diagnostics.

Siddaway R, Glembocki AI, Arnoldo A, Staunton J, Liu APY, Yuki KE, Yu M, Cohen-Gogo S, Shlien A, Villani A, Whitlock JA, Hitzler J, Tabori U, Levine AB, Lafrenière A, Nagy A, Chen H, Ngan BY, Somers GR, Abdelhaleem M, Chami R, Hawkins C

Nature medicine2025

DOI: 10.1038/s41591-025-03848-8 PMID: 40676318

Il-6 knockout reduces doxorubicin-induced toxicity in the developing mouse brain.

Yeung J, Quach H, Wong AP, Wheeler AL, Weksberg R, Guger SL, Schachar RJ, Ito S, Hitzler J, Nieman BJ

Brain, behavior, and immunity2025

DOI: 10.1016/j.bbi.2025.06.034 PMID: 40588079

Prolonged Hypogammaglobulinemia in a Child With Down Syndrome After Treatment of Acute Lymphoblastic Leukemia With Immunochemotherapy Including Blinatumomab.

Pabari R, Hitzler J

Pediatric blood & cancer2025Senior author

DOI: 10.1002/pbc.31626 PMID: 39984174

An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup.

Gower M, Li X, Aguilar-Navarro AG, Lin B, Fernandez M, Edun G, Nader M, Rondeau V, Arruda A, Tierens A, Eames Seffernick A, Pölönen P, Durocher J, Wagenblast E, Yang L, Lee HS, Mullighan CG, Teachey D, Rashkovan M, Tremblay CS, Herranz D, Itkin T, Loghavi S, Dick JE, Schwartz G, Perusini MA, Sibai H, Hitzler J, Gruber TA, Minden M, Jones CL, Dolgalev I, Jahangiri S, Tikhonova AN

Science translational medicine2025

DOI: 10.1126/scitranslmed.adr2012 PMID: 39742502

Preventing infection-related mortality in children with Down syndrome during treatment for acute lymphoblastic leukemia

Co-investigatorCIHR2026Project Grant

Principal investigators: Guidos, Cynthia J

Keywords: Acute Lymphoblastic Leukaemia; Companion Biology Study Of Clinical Trial Biospecimens; Down Syndrome; Immune Profiling; Infection-Related Mortality

$921,824

Genetic modifiers of chemotherapy-induced neurotoxicity identified in recombinant inbred mice

Co-investigatorCIHR2024Project Grant

Principal investigators: Nieman, Brian J

Keywords: Brain Health; Chemotherapy; Childhood Cancer; Genetics; Mouse Models; Neuroimaging; Side Effects; Survivorship

$1,105,426

How does chemotherapy to treat childhood cancer affect brain development?

Co-investigatorCIHR2019Project Grant

Principal investigators: Nieman, Brian J

Keywords: Acute Lymphoblastic Leukemia; Chemotherapy; Childhood Cancer; Cognitive Outcomes; Magnetic Resonance Imaging; Mouse Models; Survivorship

$933,300

Mechanisms and Risk Stratification for Treatment of Acute Myeloid Leukemia in Children with Down syndrome

Nominated PICIHR2015Operating Grant

Principal investigators: Hitzler, Johann H

Keywords: Acute Myeloid Leukemia; Ancillary Study To Clinical Trial In Ds-Aml; Digital Pcr; Down Syndrome; Error-Corrected Sequencing; Gata1; Minimal Residual Disease; Xenografts

$773,060

Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood leukemia Survivors: N-PhenoGENICS

Principal investigatorCIHR2011Team Grant: Childhood Cancer - Late Effects of Treatment

Principal investigators: Ito, Shinya; Guger, Sharon; Hitzler, Johann H; O'Connor, Deborah L; Schachar, Russell J; Spiegler, Brenda; Weksberg, Rosanna

Keywords: Adverse Drug Reaction; Attention Deficit; Children; Epigenetics; Folate; Genome; Leukemia; Methotrexate; Neurocognitive Function; Vitamin B12

$1,633,381

Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood leukemia Survivors: N-PhenoGENICS

Principal investigatorCIHR2010Team Grant: Childhood Cancer - Late Effects of Treatment -LOI

Principal investigators: Ito, Shinya; Guger, Sharon; Hitzler, Johann H; O'Connor, Deborah L; Schachar, Russell J; Spiegler, Brenda; Weksberg, Rosanna

Keywords: Adverse Drug Effects; Attention Deficit; Brain; Children; Leukemia; Methotrexate

$5,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Johann Hitzler

Research

Latest papers

Latest funding

IFN-&#x3b3; drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.

DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia.

T-Cell Lymphoblastic Lymphoma in a Child With Trisomy 21: A Unique Case Demonstrates the Need for Malleability in Therapy.

Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.

The "route cause" of methotrexate-induced brain structure changes in a juvenile mouse model: Comparison of systemic and CNS-targeted chemotherapy.

Vincristine-induced brain toxicity is reduced with prevention of peripheral axon degeneration in Sarm1 knockout mice.

Clinical utility of targeted RNA sequencing in cancer molecular diagnostics.

Il-6 knockout reduces doxorubicin-induced toxicity in the developing mouse brain.

Prolonged Hypogammaglobulinemia in a Child With Down Syndrome After Treatment of Acute Lymphoblastic Leukemia With Immunochemotherapy Including Blinatumomab.

An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup.

Preventing infection-related mortality in children with Down syndrome during treatment for acute lymphoblastic leukemia

Genetic modifiers of chemotherapy-induced neurotoxicity identified in recombinant inbred mice

How does chemotherapy to treat childhood cancer affect brain development?

Mechanisms and Risk Stratification for Treatment of Acute Myeloid Leukemia in Children with Down syndrome

Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood leukemia Survivors: N-PhenoGENICS

Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood leukemia Survivors: N-PhenoGENICS

Frequent collaborators

Shinya Ito

Rosanna Weksberg

Lillian Sung

Mohamed Abdelhaleem

Sheila Weitzman

Adam Shlien

Uri Tabori

David Malkin

Cynthia Hawkins

Joseph Beyene

Mark Minden

Vijay Ramaswamy

Gregory Schwartz

Thomas Kislinger

James Whitlock

Lee Dupuis

Jennifer Crosbie

Faiyaz Notta

Adele Changoor

Jordan Mak

Catherine Goudie

David Murray

Federico Gaiti

Daniel Coutu

David Colantonio

Jason Berman

Yigal Dror

Thierry Mallevaey

Annie Huang

Sumit Gupta

Margarete Akens

Uma Athale

Paul Gibson

M Cheryl Alyman

Yutaka Yasui

Gelareh Zadeh

Cari Whyne

IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.